Top Value Stocks To Buy Right Now

tags:PLT,TROX,CRME,

Generally speaking, growth stocks are expensive. They trade for high multiples of everything, with prices based on potential rather than current results. Paying up for a growth stock makes sense if the price is reasonable based on the company's growth prospects, but unchecked optimism can sometimes push growth stock prices beyond reason.

Occasionally, a growth stock falls out of favor. When that happens, the stock may start looking more like a value stock, even though the above-average growth potential is still there. Three of our Motley Fool contributors think Cypress Semiconductor (NASDAQ:CY), Skechers (NYSE:SKX), and Teva Pharmaceutical (NYSE:TEVA) fall into this category. Here's what you need to know about these deep-value growth stocks.

Image source: Getty Images.

Top Value Stocks To Buy Right Now: Plantronics Inc.(PLT)

Advisors' Opinion:

• [By Joseph Griffin]

  TRADEMARK VIOLATION NOTICE: “Brian S. Dexheimer Sells 500 Shares of Plantronics (PLT) Stock” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3355123/brian-s-dexheimer-sells-500-shares-of-plantronics-plt-stock.html.

• [By Stephan Byrd]

  Lapides Asset Management LLC reduced its position in shares of Plantronics Inc (NYSE:PLT) by 36.3% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 42,200 shares of the technology company’s stock after selling 24,100 shares during the quarter. Lapides Asset Management LLC’s holdings in Plantronics were worth $3,218,000 at the end of the most recent quarter.

• [By Logan Wallace]

  Plantronics (NYSE: PLT) and Ciena (NYSE:CIEN) are both mid-cap computer and technology companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership and dividends.

• [By Motley Fool Transcribers]

  Plantronics Inc  (NYSE:PLT)Q3 2019 Earnings Conference CallFeb. 05, 2019, 5:00 p.m. ET

  Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

  Operator

Top Value Stocks To Buy Right Now: Tronox Limited(TROX)

Advisors' Opinion:

• [By Joseph Griffin]

  Wolverine Asset Management LLC acquired a new stake in Tronox Ltd (OTCMKTS:TROX) in the second quarter, HoldingsChannel.com reports. The firm acquired 27,200 shares of the basic materials company’s stock, valued at approximately $535,000.

• [By Max Byerly]

  Shares of Tronox Ltd (OTCMKTS:TROX) traded down 8.6% on Tuesday . The company traded as low as $10.95 and last traded at $11.09. 1,237,777 shares changed hands during trading, a decline of 7% from the average session volume of 1,334,449 shares. The stock had previously closed at $12.14.

• [By Maxx Chatsko]

  Shares of Tronox (NYSE:TROX) jumped over 20% today after the company announced it had filed a joint motion with the U.S. Federal Trade Commission to delay the appeal schedule regarding the review of its proposed acquisition of Cristal. The move suggests the titanium dioxide manufacturer and the FTC are making progress toward a compromise over the acquisition of the Saudi-based chemicals producer, which has been under intense regulatory scrutiny for two years. 

• [By Shane Hupp]

  Get a free copy of the Zacks research report on Tronox (TROX)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top Value Stocks To Buy Right Now: Cardiome Pharma Corporation(CRME)

Advisors' Opinion:

• [By Logan Wallace]

  Cardiome Pharma Co. (TSE:COM) (NASDAQ:CRME) – Stock analysts at Zacks Investment Research issued their Q2 2018 EPS estimates for Cardiome Pharma in a research note issued on Tuesday, May 22nd. Zacks Investment Research analyst J. Vandermosten anticipates that the biopharmaceutical company will post earnings per share of ($0.26) for the quarter.

• [By Stephan Byrd]

  Here are some of the media stories that may have impacted Accern’s rankings:

  Get Cardiome Pharma alerts: Cardiome Pharma Corp (TSE:COM): Should The Recent Earnings Drop Worry You? (finance.yahoo.com) Pacira Pharmaceuticals Gets a Hold Rating from Canaccord Genuity (analystratings.com) As of May, 21 Analysts See $-0.20 EPS for Cardiome Pharma Corp. (CRME) (thecasualsmart.com) Cardiome Pharma Corp. (CRME) stock added 0.33% off its SMA-20 (thestocksnews.com) Cardiome Pharma (CRME) Upgraded to Sell at ValuEngine (americanbankingnews.com)

  Shares of CRME traded down $0.01 during mid-day trading on Wednesday, reaching $2.29. The company’s stock had a trading volume of 730 shares, compared to its average volume of 138,610. The firm has a market cap of $80.20 million, a price-to-earnings ratio of -2.53 and a beta of 0.19. The company has a debt-to-equity ratio of 2.47, a quick ratio of 3.99 and a current ratio of 4.80. Cardiome Pharma has a 52 week low of $2.28 and a 52 week high of $2.30.

• [By Lisa Levin]

  Cardiome Pharma Corp. (NASDAQ: CRME) is expected to post quarterly loss at $0.07 per share on revenue of $6.34 million.

  Quest Resource Holding Corporation (NASDAQ: QRHC) is estimated to post quarterly loss at $0.09 per share on revenue of $24.85 million.